Our firm, Foley Hoag, has a webpage describing the major impacts of PAMA on the diagnostics industry, here.
Details about the Webinar and conference we hosted on May 14, 2014, are stored after the break.
Back on May 14, 2014, we hosted -- along with BIO, NVCA, the Personalized Medicine Coalition, and ADVI, a panel of speakers on implications of PAMA for the lab marketplace on Wednesday, May 14, in Washington. The event also offered had dial-in teleconference. Details after the break.
On April 1, the Protecting Access to Medicare Act of 2014 (PAMA) was enacted into law. Section 216, entitled Improving Medicare Policies for Clinical Diagnostic Laboratory Tests, modernizes the Medicare payment system for clinical laboratory tests with the establishment of a market-based payment system. This is the most significant modernization of the Clinical Laboratory Fee Schedule (CLFS) since the introduction of the CLFS in 1984.
A Panel Discussion With
- Dan Todd, Health Policy Advisor, Senate Finance Committee - PAMA Overview / CLFS Reform to Market Based Pricing
- Elaine Jeter, M.D., Medical Director, Palmetto GBA - What to Expect from Private Payers and the Role of MolDx
- Louis Jacques, M.D., ADVI (former Director, Coverage & Analysis Group, CMS) - The role of CMS and FDA in Clinical Utility
- Brian Carey, Foley Hoag, LLP - Issues to Watch for Implementation
Moderators:
Marc Samuels, ADVI, and Bruce Quinn, M.D., Ph.D., Foley Hoag LLP
EVENT DATE & TIME
Wednesday, May 14, 2014 12:00 pm - 3:00 pm
Wednesday, May 14, 2014 12:00 pm - 3:00 pm
LOCATION
Biotechnology Industry Organization
1201 Maryland Avenue SW
9th Floor
Washington, DC 20024
Biotechnology Industry Organization
1201 Maryland Avenue SW
9th Floor
Washington, DC 20024
RSVP: PAST EVENT: REGISTRATION CLOSED
